Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 12 Breast Neoplasms 7 Neoplasm Metastasis 5 Lymphoma 5 Multiple Myeloma 4 Leukemia 4 Hematologic Neoplasms 4 Colorectal Neoplasms 4 Prostatic Neoplasms 3 Lung Neoplasms 3 Leukemia, Myeloid, Acute 3 Depression 3 Urinary Bladder Neoplasms 2 Triple Negative Breast Neoplasms 2 Ovarian Neoplasms 2 Motor Activity 2 Malignant Female Reproductive System Neoplasm 2 Glioblastoma 2 Fatigue 2 Fallopian Tube Neoplasms 2 Endometrial Neoplasms 2 Caregiver Burden 2 Anxiety Disorders 2 Advanced Malignant Solid Neoplasm 2 Thyroid Neoplasms 1 Stroke 1 Stress Disorders, Post-Traumatic 1 Squamous Cell Carcinoma of Head and Neck 1 Sleep Initiation and Maintenance Disorders 1 Signs and Symptoms 1

Interventions

pembrolizumab 137 Nivolumab 116 Ipilimumab 68 Cyclophosphamide 33 Specimen Handling 31 Magnetic Resonance Spectroscopy 28 trametinib 23 binimetinib 22 fludarabine 21 Interleukin-2 20 dabrafenib 19 relatlimab 17 encorafenib 17 Biopsy 17 CTLA-4 Antigen 16 cemiplimab 15 atezolizumab 15 aldesleukin 15 Radiosurgery 15 fludarabine phosphate 14 Opdualag 14 Radiotherapy 11 lenvatinib 10 Blood Specimen Collection 10 lifileucel 9 Paclitaxel 8 Cisplatin 8 Bevacizumab 8 spartalizumab 7 cobimetinib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × Palliative Care × 1 year × Clear all

NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡